In their research, scientists have identified a change in gene expression in the placenta of pregnant women with cancer. The ...

Q1 2025 Earnings Call Transcript May 2, 2025 Operator: Thank you for standing by. Hello and welcome to the Summit Therapeutics Q1 2025 Earnings Conference Call. I would now like to turn the call over ...

Q1 2025 Earnings Call Transcript May 2, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.37396 EPS, expectations were $-0.19. Melanie Solomon: Greetings and welcome to ...

Read the full guideline update, “Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update” at ... immunotherapy, chemotherapy, pathology, and germline testing. Dr.

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, ...

Researchers at Karolinska Institutet have uncovered a unique ability of a special subtype of natural killer cells in the ...

The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity i | Immunology ...

Amber Kelleher-Andrews, a renowned matchmaker, has passed away at 56 after battling stage 4 ovarian cancer. Diagnosed in 2017, the cancer briefly went into remission before returning aggressively.

INX-315, a CDK2 inhibitor, targets CCNE1-amplified platinum-resistant ovarian cancer, addressing a significant unmet need in this patient population. The FDA's fast track designation facilitates ...